Abstracts tagged "Employment and Work Disability"

Abstract Number: 3056 • 2016 ACR/ARHP Annual Meeting
Efficacy of a Work Disability Prevention Program for People with Rheumatic and Musculoskeletal Conditions: A Randomized Controlled Trial
Julie J. Keysor^1,2, Michael P. LaValley³, Carrie Brown⁴, David T. Felson⁵, Rawan AlHeresh⁶, Molly Vaughan⁷, Robert A. Yood⁸, John Reed⁹ and Saralynn Allaire¹⁰, ¹Physical Therapy, Boston University, Boston, MA, ²Clinical Epidemiology Research and Training, Boston University School of Medicine, Boston, MA, ³Biostatistics, Boston University School of Public Health, Boston, MA, ⁴Boston University School of Public Health, Boston, MA, ⁵Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁶Rheumatology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, ⁷635 Commonwealth Avenue, Room 651, Boston University College of Health & Rehabilitation Sciences, Boston, MA, ⁸Fallon Clinic, Worcester, MA, ⁹Rheumatology, Reliant Medical Group, Worcester, MA, ¹⁰Clinical Epidemiology Research and Training Unit, Clinical Epidemiology, BUSM, Boston, MA
Background/Purpose: Rheumatic and musculoskeletal conditions are leading causes of work disability. A previous trial showed a preventive work disability intervention delivered by vocational rehabilitation counselors…
Abstract Number: 449 • 2013 ACR/ARHP Annual Meeting
Work Instability In Early Rheumatoid Arthritis With Elevated Risk Of Employment Loss: Effects Of Adalimumab/Methotrexate Combination Therapy Versus Methotrexate In a Randomized Clinical Trial
Arthur Kavanaugh¹, Josef S. Smolen², Arijit Ganguli³, Hartmut Kupper³, Mary Cifaldi³, Naijun Chen³ and Dennis Revicki⁴, ¹University of California, San Diego, La Jolla, CA, ²Medical University of Vienna, Vienna, Austria, ³AbbVie Inc., North Chicago, IL, ⁴United BioSource, Bethesda, MD
Background/Purpose: Intensive treatment of early rheumatoid arthritis (RA) has been shown to reduce functional disability over time and to positively impact employment outcomes. Adalimumab (ADA)…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.